After nine years at the company, Mats Blom, Chief Financial Officer, will leave Zealand Pharma at the end of March 2019.
Following the resignation of Britt Meelby Jensen on 26 November 2018, the Board of Directors has decided that Britt will be released from her duties as President and CEO as of 28 February 2019. Adam Steensberg, MD, Executive Vice President and Chief Medical and Development Officer is appointed interim CEO as of 1 March 2019, while also maintaining his current responsibilities.
“Zealand is in a strong financial position with an exceptional outlook for the coming years. Although I am sad to see both Britt and Mats leave, an experienced and capable Management team is in place to deliver on the strategy and opportunities ahead. I am thankful for Britt’s and Mats’ contributions to Zealand. Under their leadership, Zealand has transformed into a company with a late-stage proprietary pipeline, a highly competent organization, a dual listing and physical presence in the U.S. as well as multiple future value drivers. I wish them both the best in their future endeavors,” says Martin Nicklasson, Chairman of Zealand.
The Board initiated an international search for a new President and CEO end November 2018 and the process is progressing according to plan, with a short list of candidates being interviewed. A search for a new CFO has been initiated.